| 101.21 2.15 (2.17%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 120 | 1-year : | 140.16 |
| Resists | First : | 102.73 | Second : | 120 |
| Pivot price | 99.59 |
|||
| Supports | First : | 97.65 |
Second : | 94.51 |
| MAs | MA(5) : | 99.03 |
MA(20) : | 99.76 |
| MA(100) : | 94.25 |
MA(250) : | 87.66 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4  |
| %K %D | K(14,3) : | 58.7 |
D(3) : | 47.5 |
| RSI | RSI(14): 59.2 |
|||
| 52-week | High : | 103.51 | Low : | 63.79 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XBI ] has closed below upper band by 24.6%. Bollinger Bands are 25.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 101.37 - 101.67 | 101.67 - 102.01 |
| Low: | 98.35 - 98.72 | 98.72 - 99.13 |
| Close: | 100.56 - 101.12 | 101.12 - 101.74 |
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Wed, 04 Sep 2024
The 8 Best S&P 500 ETFs Of September 2024 - Forbes
Sun, 01 Sep 2024
Best SPDR ETFs to Buy and Hold - Kiplinger's Personal Finance
Mon, 01 Jul 2024
Best SPDR ETFs Of September 2024 - Forbes
Fri, 21 Jun 2024
Is SPDR S&P North American Natural Resources ETF (NANR) a Good Buy Right Now? - Yahoo Finance
Fri, 14 Jun 2024
Is SPDR Portfolio S&P 500 High Dividend ETF the Best Dividend ETF for You? - The Motley Fool
Wed, 12 Jun 2024
Is the SPDR S&P 500 ETF Trust a Millionaire-Maker? - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|